Plandai's Upcoming Weight Loss Study Primed to Outperform Competing Trials

Marketwired

BALTIMORE, MD--(Marketwired - Aug 5, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes in a just published article that with a product that likely has the highest nutrient absorption rate into the bloodstream (bioavailability) in the industry, Plandai Biotechnology, Inc. (OTCQB: PLPL) appears to have a leg up on the competition in a competitive product category worth hundreds of millions in annual sales.

Later this year, Plandai plans to test the effects of Phytofare™ Catechin Complex in inducing weight loss, while also improving cholesterol and lowering blood pressure. The human clinical trial will involve 90 subjects, including a placebo group, over three months and will include full blood panels in addition to measuring overall weight loss and changes in fat percentages and mood. Phytofare™ should be able to demonstrate significant health benefits, including weight loss, owing to its higher absorption levels.

In a recent meta-analysis of weight loss studies, on average, green tea extract was causative for body weight loss (at least 12 weeks in length) with more weight loss occurring in those that did not habitually consume caffeine. In addition, a 2009 study reported in the American Journal of Clinical Nutrition, noted that men who consumed roughly 660mg worth of catechins lost nearly twice as much weight -- 5.3 compared to 2.9 pounds -- than those who consumed 10% of that figure. Plus, the men in this study reported that they experienced greater losses in waist size and body mass index.

The Plandai trial is likely to demonstrate significantly greater bioavailability than the typical 2-13% garnered by competing products, which should foster better-than-historical results. Moreover, the Phytofare™ Catechin Complex is comprised of more than just the EGCG catechin, which should pack an even greater punch through its absorption and weight loss effect. Finally, the tolerability of the Phytofare™ Catechin Complex, due to its very construction, should be much greater than the high levels of EGCG on its own.

With all of these positive attributes in its corner, Plandai is on the verge of changing how we approach weight loss on its way to generating substantial revenue in the nutriceutical space. 

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com
View Comments (0)